Objective: To observe the clinical therapeutic effect of Pyretic Arthralgia granules in treating rheumatoid arthritis of moist heat arthralgia spasm syndrome,so as to provide scientific evidence in clinical Medication.Methods: Adopted random and positive parallel contrast methods,60 cases of active stage rheumatoid arthritis(RA) patients whom were differentiated of symptoms and signs as moist heat arthralgia spasm syndrome were divided into groups.Experimental group took Pyretic Arthralgia granules 2.0 g every time and 3 times a day orally;control group took Loxonin orally,60 mg every time and 3 times a day.Both course of treatment in two sets were 4 weeks.Results: Experimental group and control group all could improve present symptoms,physical signs and physical-chemical index.There was not significance variance in two groups comparing the disease therapeutic effect with the therapeutic effect of syndrome of traditional Chinese medicine.Conclusion: Pyretic Arthralgia granules has the effects of detumescence,alleviating pain and improving Joint function,and has not obvious poison and side reaction.It is good for further generalizing and applying.

Target therapy is a major progress in treatment of advanced colorectal cancer. Cetuximab and bevacizumab are the most widely used target agents in colorectal cancer, which target against EGFR and VEGF respectively. The addition of target agent to chemotherapy improve efficacy and prolong survival in the first line setting, as well as in the second line setting. The increased respectability of liver metastases from colorectal cancer is of great importance, k-ras gene mutation is a definite predictor of cetuximab, however, there is no clear predictor for bevacizumab.

The development of anti-epidermal growth factor receptor monoclonal antibodies (anti-EGFR McAbs) marked a significant milestone in metastatic colorectal cancer (mCRC) treatment. The addition of anti-EGFR McAb can greatly improve quality of life of mCRC patients and mCRC prognosis and markedly increases the overall survival rate from 6 months to nearly 30 months. KRAS and NRAS mutations contribute to the primary resistance to anti-EGFR therapy and can serve as well-established predictive markers for pa-tient selection. Apart from the RAS family, other molecular alteration in EGFR signaling pathway may also compromise the efficacy of anti-EGFR treatment. In addition, patients who responded to anti-EGFR treatment eventually develop acquired drug resistance within 13 and 18 months. In this review, the mechanisms underlying the primary and secondary resistance to anti-EGFR therapy are summa-rized, and a possible strategy to circumvent drug resistance is proposed. We hope this review can provide compelling evidence, deeper insights, and reasonable guidance to facilitate the precise molecular targeted therapy of mCRC.

High resolution melting ( HRM) analysis is a real-time PCR based technique which can detect DNA sequence polymorphism .Immediately after routine PCR with saturated fluorescent dye , melting transition of the amplicon was monitored and fluorescence was collected .According to the different melting curve, single base differences can be distinguished .HRM is a low -cost, single -step, closed -tube, accurate and rapid method , which has aroused general concern .Rapid and sensitive detection of the clinical pathogens is critical to diagnosis of infectious diseases .However , clinical research on application of HRM in infectious disease pathogen identification and drug resistance , especially melting curve analysis based bedside technology integration will provide strong support for the diagnosis and treatment of infectious diseases.

OBJECTIVE: To observe therapeutic effect and adverse reaction of the combination of Concha merelricis Seu cyclinae powder with 0. 02% furacilin solution in treating dermatitis vulvae and eczema. METHODS: Thirty outpatients (9 men and 21 women with the average age of 47. 1 years old) were treated with Concha meretricis Seu cyclinae powder and 0. 02% furacilin solution by wet dressing or external use twice daily for three weeks. RESULTS: 21 cases were cured (70%); 6 cases were significant recovery (20%); 2 cases were effective (6. 66%) and 1 cases was ineffective (3. 33%), The total effective rate was 90. 0% and no adverse reaction was found. CONCLUSIONS: Concha meretricis Seu cyclinae powder combined with 0. 02% furacilin solution is one of the effective therapy in the treatment of dermatitis vulvae and eczema.

Objective To explore the effect of formaldehyde on learning and memory and the activity of superoxide dismutase (SOD) in the cerebral tissues. Methods 40 ICR mice were randomly divided into four gropes: A-control group (NS was added into water bottle), B, C, D-three formaldehyde dose groups (0.1, 0.2, 0.4% formaldehyde solution were added into water bottles). After 30 days of treatment, the ability of learning and memory were evaluated by Morris watermaze test and step-down test and the activity of SOD in the cerebral tissues was determined. Results In the Morris watermaze test (the fifth day), escapelaten latence in group C[ (29.23?5.56)s] and D[ (37.36?7.39)s] were significantly longer than group A[ (21.65?5.81)s](P

The addition of HER2-targeted therapy has markedly improved the survival and prognosis of patients with advanced gastric cancer. Inhibiting the HER2 signaling pathway has become the backbone treatment for advanced HER2-positive gastric cancer in the first-line setting. TOGA trial established trastuzumab in combination with cisplatin and 5-flurouracil as the standard first-line treat-ment. In the post-TOGA era, combinations of trastuzumab with other chemotherapy agents were proven to be effective as both the second-line treatment and the conversion treatment. Such combinations are promising in the neoadjuvant treatment for locally ad-vanced gastric cancer. Research focuses on the development of novel anti-HER2 agents in combination with agents targeting against other signal pathways. Real-time monitoring of the gene expression profile is the key to discovering the mechanism of trastuzumab re-sistance. The preliminary results of existing clinical trials have shown potential to overcome resistance to trastuzumab. In this review, we summarized the treatment advancement for HER2 positive gastric cancer and the direction for future development, thereby provid-ing guidance on clinical practice.

Objective:To explore the role of clinical pharmacists in the use of antiplatelet drugs in the patients with PCI in periop-erative period in order to improve the clinical treatment effect and reduce the incidence of adverse drug reactions. Methods:According to the latest antiplatelet drug treatment guidelines and the related literatures, the causes of acute upper gastrointestinal bleeding induced by triple antiplatelet drugs were analyzed in one case of postoperative patients with PCI, and the rationality of the drug use and the treatment of bleeding were discussed, and the related suggestions were put forward for clinics. Results:In order to ensure the clinical safety and the rational use of drugs, the patients with high risk of bleeding and high thrombosis events should carefully select new anti-platelet drugs, and anti ischemic drugs with good efficacy and low bleeding risk were the first choices. Conclusion:In order to ensure medication safety and effectiveness, clinical pharmacists should actively participate in clinical rational drug use through giving relative suggestions and playing active roles in the rational use of antiplatelet drugs.

Objective To evaluate the safety and efficacy of dosage-escalated sorafenib in pa-tients with metastatic renal cell carcinoma. Methods Twelve male patients and 4 female patients with median age of 53 (37-71 years) were included in this study. They were with refractory meta-static renal-clear-cell carcinoma and received sorafenib from 800 mg/d to 1200mg/d or 1800 mg/d gradually until intolerable or disease progression occurred. Overall response rate, toxicity and progres-sion free survival (PFS) were recorded and analyzed. Results The median follow-up was 11 months (9-16 months). The overall rate of objective response and disease control rate were 44%(7/16)and 81%(13/16), respectively. Serious adverse effects (≥Grade Ⅲ) included hand-foot skin reaction (25%, 4/16), mucositis (19%, 3/16), diarrhea (19%, 3/16), hypertension (12%, 2/16) and my-elosuppression (12%, 2/16). PFS for high risk patient was 9.2 months at the end of this study. Conclusions The dosage-escalated sorafenib could obtain a high response rate and prolong PFS of high-risk patients. The toxicities are tolerable for metastatic renal cell carcinoma patients treated with sorafenib.

Objective To evaluate the safety and efficacy of sorafenib as first line treatment in patients with metastatic renal cell carcinoma. Methods Eleven patients with metastatic renal cell carcinoma after radical nephrectomy and 1 patient with locally advanced renal cell carcinoma and unre-sectable primary renal tumor were eligible for this study. The regimen was oral intake of sorafenib (400 mg twice daily) until the disease progression or toxicity becoming intolerable. Results All pa-tients were evaluable for response and toxicity assessment. The overall objective response rate and dis-ease control rate were 25%(3/12) and 83%(10/12, 3 partial responses and 7 disease stabilizations). The actuarial 6-month progression-free survival was 83% (10/12), while the median survival time was 16 months. The most common adverse effects included hand-foot skin reaction, rash, alopecia and hy-pertension. Conclusion Sorafenib is effective and safe as first line treatment for patients with meta-static renal cell carcinoma.